The prevalence and effects of treatments of rapidly progressive interstitial lung disease of dermatomyositis/polymyositis adults: A systematic review and meta-analysis

医学 内科学 间质性肺病 多发性肌炎 皮肌炎 环磷酰胺 人口 存活率 胃肠病学 肺 化疗 环境卫生
作者
Hongli Wang,Jiyang Lv,Juan He,Wenqi Wu,Yuchao Zhong,Siyang Cao,Yueming Cai,Qingwen Wang
出处
期刊:Autoimmunity Reviews [Elsevier BV]
卷期号:22 (8): 103335-103335 被引量:37
标识
DOI:10.1016/j.autrev.2023.103335
摘要

Rapidly progressive interstitial lung disease (RP-ILD) clearly harms the prognoses of dermatomyositis/polymyositis (DM/PM) patients, however there is a dearth of numerical prevalence and therapy comparison in this field. Therefore, the purpose of this study was to determine the prevalence of RP-ILD in DM/PM patients and compare prognoses, including remission rate and survival data, between treatments. Studies with reports of RP-ILD in DM/PM patients and studies with definite remission and/or survival data of DM/PM-RP-ILD were included in the study. Data sources were Pubmed, Embase, and Cochrane Library without language restrictions. Two authors (WHL and WWQ) extracted independently the data. Estimates of the pooled effects were calculated using the Mantel-Haenszel technique (random effects). The prevalence meta-analysis included 18 papers with 6058 DM/PM patients, and 31 papers were analyzed for treatment effects, including remission rate, 6-month survival rate, 1-year survival rate, and 5-year survival rate. Database search yielded 1816 articles. In the DM/PM population, the combined prevalence of RP-ILD was 8.9% (95% CI, 5.8% to 12.1%). Patients with RP-ILD have a remission rate of 58.4% (95% CI, 47.3% to 69.4%), with biologic treatment with the highest remission rate, followed by triple therapy (defined as adding a third intravenous medication, including cyclophosphamide and immunoglobulin). Biologics therapy had the highest overall survival rate at six months (95% CI, 49.8% to 73.9%), followed by cDMARDs, plasma exchange, and triple therapy. The 1-year survival rate was 77.4% (95% CI, 66.7% to 88.1%), and triple therapy and cDMARDs had the best survival rates. The 5-year survival rate was 40.0% (95% CI, 10.0% to 69.9%). The prevalence of RP-ILD in DM/PM was approximately 8.9%, with a poor long-term prognosis. The use of biological agents appears to provide the best therapeutic outcomes, providing RP-ILD management with a novel evidence-based therapy. The use of strong immunosuppressive treatments may result in life-threatening side effects, thus clinicians must closely monitor the condition.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
万能图书馆的应助被春日午后采纳,获得10
1秒前
Atlantis30发布了新的文献求助10
1秒前
2秒前
予诺发布了新的文献求助10
5秒前
WC241002292完成签到,获得积分10
6秒前
7秒前
酷波er的应助被Tao2023采纳,获得30
9秒前
wxy完成签到,获得积分10
9秒前
忧虑的青旋完成签到,获得积分10
9秒前
小陈发布了新的文献求助10
10秒前
斯文败类的应助被迟安歌采纳,获得10
10秒前
张汉三完成签到 ,获得积分10
11秒前
Yumm完成签到 ,获得积分10
11秒前
wxy发布了新的文献求助10
12秒前
快乐小狗旺旺喵完成签到,获得积分20
15秒前
15秒前
15秒前
小张呢好完成签到,获得积分10
16秒前
科研通AI6.2的应助被action采纳,获得10
19秒前
ding的应助被小陈采纳,获得10
19秒前
执着的尔容完成签到,获得积分10
23秒前
研友_VZG7GZ的应助被863采纳,获得10
24秒前
Bright完成签到 ,获得积分10
25秒前
秋风的应助被DW采纳,获得10
27秒前
Pursue。完成签到,获得积分10
27秒前
29秒前
TPolymer完成签到,获得积分10
32秒前
脑洞疼的应助被扶竹苏春采纳,获得10
33秒前
化学废材完成签到,获得积分10
34秒前
CodeCraft的应助被hyska采纳,获得10
35秒前
含蓄书桃发布了新的文献求助10
36秒前
36秒前
37秒前
38秒前
健康的魔镜完成签到 ,获得积分10
40秒前
华无剑的应助被DW采纳,获得10
40秒前
41秒前
小乐乐完成签到 ,获得积分10
41秒前
斯文败类的应助被淡淡青枫采纳,获得10
43秒前
44秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8188339
求助须知:如何正确求助?哪些是违规求助? 9576127
关于积分的说明 21845709
捐赠科研通 7786389
什么是DOI,文献DOI怎么找? 3435292
关于科研通互助平台的介绍 2559588
邀请新用户注册赠送积分活动 2482196